Novartis Receives FDA Approval of Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanoma

:Basel, April 30, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Tafinlar ® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news